Vimarsana
Biggest News Aggregation in the World

Page 3 - Mathilde Bohin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mathilde Bohin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mathilde Bohin Today - Breaking & Trending Today

Oncodesign Precision Medicine (OPM) Announces its IPO Through Direct Listing on Euronext Access + Paris - Vimarsana News

Oncodesign Precision Medicine (OPM) Announces its IPO Through Direct Listing on Euronext Access + Paris

Direct listing of OPM on Euronext Access Paris on 5 October 2022 Q&A available (only in French): click here Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63;

The General Meeting of Oncodesign Authorises the Allocation of Oncodesign Precision Medicine (OPM) Shares to Oncodesign Shareholders - Vimarsana News

The General Meeting of Oncodesign Authorises the Allocation of Oncodesign Precision Medicine (OPM) Shares to Oncodesign Shareholders

Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held Regulatory News: Oncodesign's (Paris:ALONC) General Meeting held on September 30, 2022, authorised the

Euronext Paris Authorises the Listing of Oncodesign Precision Medicine (OPM) Shares on Euronext Access + in Connection With the Allocation of OPM Shares to Oncodesign Shareholders - Vimarsana News

Euronext Paris Authorises the Listing of Oncodesign Precision Medicine (OPM) Shares on Euronext Access + in Connection With the Allocation of OPM Shares to Oncodesign Shareholders

IPO planned at a reference price of €0.817 per share Fundraising of €8 million, guaranteed by OPM's management, planned before the end of 2022 Availability of the Disclosure Document

Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine (OPM) on Parkinson's disease - Vimarsana News

Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine (OPM) on Parkinson's disease

CTA1 approval by the ANSM2 and the EC3 of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment in Parkinson's

IMPLANET Publishes Its 2022 Half-year Results - Vimarsana News

IMPLANET Publishes Its 2022 Half-year Results

Sharp increase in revenue for the first half of 2022 of +58%, to €4.1 million (vs. H1 2021) 52% increase in gross margin in the first half of 2022, to €2.6 million Removal of the conditions